These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 35638454)
1. Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis. Burns R; Niendorf K; Steinberg K; Mueller A; Ly I; Jordan JT; Plotkin SR; Hicks SR Am J Med Genet A; 2022 Aug; 188(8):2413-2420. PubMed ID: 35638454 [TBL] [Abstract][Full Text] [Related]
2. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Plotkin SR; Messiaen L; Legius E; Pancza P; Avery RA; Blakeley JO; Babovic-Vuksanovic D; Ferner R; Fisher MJ; Friedman JM; Giovannini M; Gutmann DH; Hanemann CO; Kalamarides M; Kehrer-Sawatzki H; Korf BR; Mautner VF; MacCollin M; Papi L; Rauen KA; Riccardi V; Schorry E; Smith MJ; Stemmer-Rachamimov A; Stevenson DA; Ullrich NJ; Viskochil D; Wimmer K; Yohay K; ; Huson SM; Wolkenstein P; Evans DG Genet Med; 2022 Sep; 24(9):1967-1977. PubMed ID: 35674741 [TBL] [Abstract][Full Text] [Related]
3. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors. Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Blakeley JO; Plotkin SR Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632 [TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis- and schwannomatosis-associated tumors: Approaches to genetic testing and counseling considerations. Goetsch Weisman A; Weiss McQuaid S; Radtke HB; Stoll J; Brown B; Gomes A Am J Med Genet A; 2023 Oct; 191(10):2467-2481. PubMed ID: 37485904 [TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008 [TBL] [Abstract][Full Text] [Related]
7. Schwannomatosis: a Realm Reborn: year one. Planet M; Kalamarides M; Peyre M Curr Opin Oncol; 2023 Nov; 35(6):550-557. PubMed ID: 37820090 [TBL] [Abstract][Full Text] [Related]
9. Updated protocol for genetic testing, screening and clinical management of individuals at risk of NF2-related schwannomatosis. Halliday D; Emmanouil B; Evans DGR Clin Genet; 2023 May; 103(5):540-552. PubMed ID: 36762955 [TBL] [Abstract][Full Text] [Related]
10. Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis. Farschtschi SC; Kluwe L; Schön G; Friedrich RE; Matschke J; Glatzel M; Weis J; Hagel C; Mautner VF Brain Pathol; 2020 Mar; 30(2):386-391. PubMed ID: 31424590 [TBL] [Abstract][Full Text] [Related]
11. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO; Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207 [TBL] [Abstract][Full Text] [Related]
12. What to know about schwannomatosis: a literature review. Schraepen C; Donkersloot P; Duyvendak W; Plazier M; Put E; Roosen G; Vanvolsem S; Wissels M; Bamps S Br J Neurosurg; 2022 Apr; 36(2):171-174. PubMed ID: 33263426 [TBL] [Abstract][Full Text] [Related]
13. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas. Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736 [TBL] [Abstract][Full Text] [Related]
14. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099 [TBL] [Abstract][Full Text] [Related]
15. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162 [TBL] [Abstract][Full Text] [Related]
16. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution. Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091 [TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution. Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060 [TBL] [Abstract][Full Text] [Related]
18. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR; Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649 [TBL] [Abstract][Full Text] [Related]
19. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Smith MJ; Kulkarni A; Rustad C; Bowers NL; Wallace AJ; Holder SE; Heiberg A; Ramsden RT; Evans DG Am J Med Genet A; 2012 Jan; 158A(1):215-9. PubMed ID: 22105938 [TBL] [Abstract][Full Text] [Related]
20. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]